Chinese COVID-19 vaccine undergoes clinical trials in UAE
The inactivated COVID-19 vaccine entered the third phase of clinical trials in the United Arab Emirates (UAE), Xinhua News Agency reported on June 24. Vaccine manufacturer China National Biotec Group (CNBG) notes that the clinical trials started officially after signing a cooperation agreement between the two parties during a video conference between Beijing, Wuhan and Abu Dhabi. Thus, this is the first vaccine developed in China, which entered the third phase of trials abroad. CNBG will collaborate with Group 42 (G42), which is located in Abu Dhabi and specializes in artificial intelligence and cloud computing, as part of clinical trials. They will also cooperate in the field of localization of vaccine production. The inactivated vaccine was developed by the Wuhan Institute of Biological Products at CNBG, and it has already passed the first and second phases of clinical trials in China. So far, it has shown sufficient effectiveness, experts noted.
Комментарии
Отправить комментарий